Resumen

CRUZ-JIMENEZ, Alicia Elvira; QUINTANAR, J, Liliana  y  LUJAN-MONTELONGO, Armando. An Overview of Antivirals for Treating Lower Respiratory Tract Infections. J. Mex. Chem. Soc [online]. 2022, vol.66, n.1, pp.130-153.  Epub 05-Dic-2022. ISSN 1870-249X.  https://doi.org/10.29356/jmcs.v66i1.1657.

Covid-19 has resulted in a worldwide epidemic (pandemic) with high morbidity and mortality, which has generated efforts in various areas of research looking for safe and effective treatments to combat the virus that generates this disease: SARS-CoV-2. However, several viruses have been emerged/adapted in the last few decades, also affecting the respiratory system. According to the world health organization (WHO), lower respiratory tract infections (LRTIs) are one of the leading causes of death worldwide, and viruses are playing important roles as the cause of these infections. In contrast to the vast repertoire of antibiotics that exist to treat bacteria-caused LRTIs, there are a very few antivirals approved for the treatment of virus-caused LRTIs, whose approach consists mainly of drug reuse. This minireview deals on the main viral pathogens that cause LRTIs and some of the most relevant antivirals to counter them (available drugs and molecules in research/clinical trials), with concise comments of their mechanism of action.

Palabras llave : Antivirals; viral respiratory diseases; drug repurpose; drug research.